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Background: Preimplantation renal biopsy provides potentially valuable information about
post-transplant renal function.
Objective: To assess the prognostic value of preimplantation kidney biopsy from older donors
in  determining 1-year post-transplant estimated glomerular ﬁltration rate MDRD-4 (eGFR).
Methods: We  evaluated a cohort of 124 renal transplant recipients from deceased donors
≥60  years old, performed at our centre between March 2008 and May 2012. Biopsies were
assessed by applying the score proposed by O’Valle et al. The overall score was stratiﬁed into
3  levels: 0–3, 4–5 and 6–8 points. Kidneys scoring >8 points were discarded. A total of 77% of
the  donors were ≥70 years.
Results: One year post-transplant, mean eGFR (SD) was lower in transplant recipients with
6–8  points (38.5 [14.1] ml/min/1.73 m2) than in the group scoring 4–5 points (46.3 [15.7]
[p  = 0.03]) and the group scoring 0–3 (49.6 [12.5] [p = 0.04]). Seven patients (19%) had eGFR
<30 ml/min/1.73 m2 1 year post-transplant in group 6–8 vs 8 (14%) in group 4–5 and nonein  group 0–3. In the logistic regression, OR (95% IC), to determine patients with 1-year
 (<30 ml/min/1.73 m2), delayed graft function (6.3 [1.9–21.3]) and acutepost-transplant eGFRrejection (5.8 [1.1–31]), were signiﬁcant. The adjusted OR of biopsy score group 6–8 vs 0–5,
was  2.2 (0.7–7.3).
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Conclusions: Allografts with higher pathologic score in preimplantation renal biopsy were
associated with a worse 1-year post-transplant eGFR. Delayed graft function and acute
rejection were signiﬁcant risk factors for 1-year post-transplant low eGFR.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Valor  pronóstico  de  la  biopsia  renal  preimplante  en  donantes  fallecidos
de  edad  avanzada  en  la  función  renal  al  an˜o  del  trasplante
Palabras clave:
Donante fallecido de edad
avanzada
Donante con criterio expandido
Biopsia renal preimplante
Trasplante renal
Filtrado glomerular
r  e  s  u  m  e  n
Antecedentes: La biopsia renal preimplante puede aportar información útil evolutiva pos-
trasplante.
Objetivo: Analizar el valor pronóstico de la biopsia renal de donantes de edad avanzada
respecto al ﬁltrado glomerular estimado MDRD-4 (FGe) al an˜o del trasplante.
Métodos: Estudiamos a 124 receptores de trasplante renal de donantes fallecidos de ≥60 an˜os,
con biopsia renal preimplante. Los trasplantes fueron realizados en nuestro centro, entre
marzo del 2008 y mayo del 2012. Las biopsias se valoraron según el baremo propuesto por
O’Valle et al. y se categorizaron en 3 grupos: 0-3, 4-5, 6-8 puntos. Se descartaron los rin˜ones
con una puntuación >8. El 77% de los donantes tenía ≥70 an˜os.
Resultados: El FGe medio (DE) del grupo 6-8 al an˜o del trasplante: 38,5 (14,1) mL/min/1,73 m2
fue menor que el del grupo 4-5: 46,3 (15,7) (p = 0,03) y del grupo 0-3: 49,6 (12,5) (p = 0,04). Se
registraron 7 (19%) pacientes con FGe < 30 mL/min/1,73 m2 en el grupo 6-8 vs. 8 (14%) en el
grupo 4-5 y ninguno en el grupo 0-3 (p = 0,17). En el análisis de regresión logística, OR (IC
95%), que valoró los pacientes con FGe < 30 mL/min/1,73 m2 al an˜o del trasplante, la función
retrasada del injerto (6,3 [1,9-21,3]) y el rechazo agudo (5,8 [1,1-31]) fueron signiﬁcativos. La
puntuación del dan˜o histológico de las biopsias, grupo 6-8 vs. 0-5, presentó un OR ajustado
no  signiﬁcativo de 2,2 (0,7-7,3).
Conclusiones: Los rin˜ones con mayor afectación histológica presentaron un menor FGe al an˜o
del  trasplante. La función renal retrasada del injerto y el rechazo fueron factores de riesgo
signiﬁcativos de un bajo FGe al an˜o del trasplante.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
Kidney transplant represents the best option for replacement
kidney therapy for patients who develop advanced chronic
kidney disease. However, the supply of young donors, who
are theoretically ideal, is limited, and does not cover the
demand among patients on the waiting list for a kidney trans-
plant. This imbalance has resulted in the growing use of older
donors, often with associated morbidity such as hypertension
and diabetes. Good clinical results are obtained with these
organs provided that these grafts are suitably and receptors
are adequate.1–4
Several scales have been developed with the aim of
assessing the quality of donors’ kidneys and to determine their
viability and post-transplant function. The Organ Procure-
ment and Transplantation Network/United Network for Organ
Sharing (OPT/UNOS) deﬁned the concept of expanded donor
criteria, but the prognostic utility of these criteria is limited,
as the concept takes into consideration heterogeneous clini-
cal proﬁles with different clinical outcomes.5,6 Other indexes
stratify graft survival more  precisely, but have a moderate
discriminatory value.7–11 The donor’s kidney biopsy provides(http://creativecommons.org/licenses/by-nc-nd/4.0/).
information that may improve the prediction of functional
outcome. However, the results that have been published are
controversial and have not been widely used.12,13
At Hospital Universitario Cruces in 2008, kidney biopsy of
deceased older donors was incorporated into the protocol to
ensure the quality of the kidney grafts being used. This study
analysed the clinical results obtained and speciﬁcally assessed
the relationship between histological lesions and glomerular
ﬁltration rate one year after transplant.
Patients  and  methods
Study  design
A retrospective cohort study of 124 kidney transplant recipi-
ents. The transplants were performed at our centre between
March 2008 and May 2012, with grafts from donors ≥60 years
of age deceased of brain death, with a preimplantation kidney
biopsy. Clinical course data was collected until May 2013, or
death or graft loss in case that one of these occurred prior to
that time.
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onor  kidney  biopsy
 biopsy was performed in all donors ≥70 years of age and in
hose 60–69 years of age with a prior history of HTA or diabetes.
n all cases, macroscopic state of the kidneys was adequate
nd the MDRD-4 estimated glomerular ﬁltration rate (eGFR)
as >60 ml/min/1.73 m2. Wedge biopsies were performed to
btain kidney samples, which were manually embedded in
arafﬁn. Fixation in formaldehyde was speeded, when nec-
ssary, in an oven at 60–70 ◦C. The samples were sliced to
–4 m and stained with haematoxylin–eosin and periodic
cid–Schiff. Histological lesions were assessed by one of a
eam of 5 pathologists at our centre by using the scale pro-
osed by O’Valle et al.14,15 (Table 1). Kidneys with a cumulative
core >8 and those with a partial assessment of 3 in lesions
f glomerulosclerosis, hyaline arteriolopathy or myointimal
lastosis were discarded. Kidneys with a score >5 were allo-
ated to recipients >60 years of age. All others were considered
o be ﬁt for any adult recipient. In the study period, a total of 39
rafts were discarded as they did not fullﬁll to the histological
riteria established.
Table 1 – Pre-implantation histological kidney lesion
scoring.
Glomerulosclerosis
0. Absence
1. 0%–10%
2. 11%–20%
3. >20%
Glomerular capsular ﬁbrosis
0. Absence
1. 0%–15%
2. 16%–40%
3. >40%
Cystic glomeruli
0. Absence
1. 0%–15%
2. 16%–40%
3. >40%
Hyaline arteriolopathy
0. Absence
1. Non-occlusive in <50% of arteries
2. Non-occlusive in >50% of arteries
3. Occlusive in >50% of arteries
Myointimal elastosis
0. Absence
1. Thickening of the intima that reduces the lumen >0%–20%
2. Thickening of the intima that reduces the lumen >21%–50%
3. Thickening of the intima that reduces the lumen >50%
Tubular atrophy
0. Absence
1. Atrophy <4/20 ﬁelds (×40)
2. Atrophy 4–10/20 ﬁelds (×40)
3. Atrophy >10/20 ﬁelds (×40)
Interstitial ﬁbrosis
0. Absence
1. Fibrosis <3/20 ﬁelds (×40)
2. Fibrosis 3–8/20 ﬁelds (×40)
3. Fibrosis >8/20 ﬁelds (×40)3 6(1):33–41 35
Immunosuppressive  treatment
Quadruple initial therapy with corticosteroids, mycopheno-
lic acid, tacrolimus and induction with two  20 mg  doses of
basiliximab intravenously was prescribed for days +0 and
+4 from the transplant. 6-Methyl-prednisolone, 125 mg  IV
was administered during the surgical procedure, 60 mg/day
were administered intravenously during the ﬁrst 3 days and
then 30 mg/day of prednisone was given orally with a sub-
sequent progressive reduction down to 5 mg/day in the ﬁrst
3 months. The initial dose of tacrolimus was 0.1 mg/kg/day
orally, with subsequent adjustments to maintain levels of
6–8 ng/ml. Patients also received 1500 mg/day of mycopheno-
late mofetil or 1080 mg/day of mycophenolate sodium orally in
3 doses. Episodes of acute rejection were treated with boluses
of 250 mg  of 6-methyl-prednisolone intravenously for 3 con-
secutive days.
Deﬁnition  of  variables
The following donor variables were included in the study:
age, gender, weight, height, creatinine on admission and prior
to blood draw, HTA, diabetes, cause of death, score for each
individual histological component, and cumulative score for
histological lesions. The following recipient variables were
included: age, gender, cause of kidney disease, method of
replacement treatment prior to transplant, previous trans-
plants and historical and current rate of panel reactive
antibodies (PRA). The following baseline and evolutionary
transplant variables were included: HLA A-B-DR incompatibil-
ities, cold ischaemia, delayed graft function, acute rejection,
death, restart of dialysis, tacrolimus and creatinine levels (ﬁrst
month, 3 months, a year, 2 years and 3 years), and protein-
uria/creatinine ratio one year after transplant.
Delayed graft function was deﬁned as a need for dialy-
sis in the ﬁrst week after transplant. The date of the last
dialysis session was accepted as the initiation of functional
recovery. Clinical episodes treated with IV boluses of 6-
methyl-prednisolone were recorded as acute rejections. The
cumulative score for histological lesions was categorised arbi-
trarily, but to optimise statistical analysis, there were classiﬁed
into 3 groups: 0–3 points, 4–5 points and 6–8 points.
The primary outcome variable was glomerular ﬁltration
rate one year after transplant, which was estimated by means
of the MDRD-4 equation. Its mean value, its categorical distri-
bution (<30, 30–59, ≥60 ml/min/1.73 m2) and the incidence of
patients with an eGFR < 30 ml/min/1.73 m2 were analysed.
Statistical  analysis
Quantitative variables were described using the mean and
standard deviation (SD) or median and quartiles (Q1–Q3) in
case of a non-normal distribution. Categorical variables were
expressed in terms of absolute frequencies and percentages.
The association between categorical variables were analysed
using the chi-squared test or Fisher’s exact test, according
to the expected values. Graft survival was estimated using
the Kaplan–Meier method. Mean eGFRs one year after trans-
plant for the histological groups were 0–3 points, 4–5 points
and 6–8 points. They were compared by means of the ANOVA
 2 0 1 36  n e f r o l o g i a.
test, with post hoc comparisosns, if in the overall test was
p < 0.05. The relationship between histological score and inci-
dence of patients with an eGFR < 30 ml/min/1.73 m2 one year
after transplant was assessed using logistic regression anal-
ysis. In the univariate analysis, the histological score and
Table 2 – Baseline, clinical and demographic
characteristics of transplant donors and patients.
Variable Total transplants,
N = 124
Donor’s age (years)
Mean (SD) 72.5 (4.9)
60–69 29 (23)
70–80 95 (77)
Male donors, N (%) 53 (43)
Donor’s cause of death, N (%)
Cerebral haemorrhage 107 (86)
Traumatic brain injury 10 (8)
Other 7 (6)
Donors with a prior history of HTA, N (%) 56  (45)
Donors with a prior history of diabetes, N (%) 17 (14)
Donor’s creatinine, mg/dl, mean (SD) 0.67 (0.17)
Donor’s MDRD-4 glomerular ﬁltration rate,
ml/min/173 m2, mean (SD)
107  (28)
Recipient’s age (years)
Mean (SD) 66.8 (6.3)
<60 14 (11)
60–69 68 (55)
70–79 42 (34)
Male recipients, N (%) 84 (68)
Cause of kidney disease, N (%)
Unknown 29 (23)
Glomerular 21 (17)
Vascular 22 (18)
Polycystitis 23 (19)
Diabetes 10 (8)
Other 19 (15)
Method of dialysis, N (%)a
Haemodialysis 82 (71)
Peritoneal dialysis 36 (29)
Time in pre-transplant dialysis, months, median
(Q1–Q3)
26 (17–41)
Recipient’s current PRA, N (%)
Negative 104 (84)
1–50 17 (14)
51–100 3 (2)
Patients with previous kidney transplant, N (%) 12 (10)
HLA A-B-DR incompatibilities, N (%)
0–2 23 (19)
3–4 92 (74)
5–6 9 (7)
Cold ischaemia, hours, mean (SD) 18.4 (3.3)
Biopsy score, N (%)
0–3 19 (15)
4–5 63 (51)
6–8 42 (34)
a Information not available in 6 patients.6;3  6(1):33–41
the clinical variables potentially inﬂuencing this result were
assessed. In the multivariate model, the histological score,
which remained ﬁxed, and the variables that had a p < 0.20
in the univariate analysis were assessed. The variables with
a higher p-value were progressively removed from the model
until a model was obtained in which all the predictive vari-
ables showed a p < 0.05. Statistical analyses were performed
with the IBM-SPSS 20.0 program.
Results
Table 2 shows the clinical and demographic characteristics
of the study patients. 77% of donors were ≥70 years of
age; 45% had HTA, and 14% had diabetes. 89% of recipi-
ents were ≥60 years of age. The eGFR of all the donors was
>60 ml/min/1.73 m2. Table 3 Table 3 speciﬁes the distribution
of histological lesions from the preimplantation kidney biop-
sies. These showed a median (Q1–Q3) of 48 glomeruli (32–71)
Table 3 – Distribution of histological lesions from
preimplantation kidney biopsies.
Type and grade of histological lesions Total biopsies,
N = 124 (%)
Glomerulosclerosis
0 11 (9)
1 85 (68)
2 27 (22)
3 1 (1)
Capsular ﬁbrosis
0 81 (65)
1 42 (34)
2 1 (1)
3 0
Cystic glomeruli
0 83 (67)
1 38 (30)
2 2 (2)
3 1 (1)
Hyaline arteriolopathy
0 83 (67)
1 40 (32)
2 1 (1)
3 0
Myointimal elastosis
0 25 (20)
1 77 (62)
2 11 (9)
3 0 (0)
Not available 11 (9)
Tubular atrophy
0 8 (7)
1 107 (86)
2 9 (7)
3 0
Interstitial ﬁbrosis
0 19 (15)
1 99 (80)
2 6 (5)
3 0
n e f r o l o g i a. 2 0 1 6;3 6(1):33–41 37
Table 4 – Overall and grouped post-transplant clinical outcomes according to histological biopsy score.
Results Biopsy score Total
0–3 4–5 6–8
No. of transplants 19 63 42 124
Immediate graft function, N (%) 14 (74) 45 (71) 25 (60) 84 (68)
Clinical rejections in the ﬁrst year, N (%) 1 (5) 7 (11) 2 (5) 10 (8)
Deaths in the ﬁrst year,. N (%)
Infectious causes 0 3 (5) 0  3 (2)
Pancreatitis 1 (5) 0 0 1 (1)
Total 1 (5) 3 (5) 0 4 (3)
Graft losses in the ﬁrst year, N (%)
Graft thrombosis 0 4 (6) 4 (10) 8 (6)
Surgical bleeding 0 0 1 (2) 1 (1)
Haemolytic-uraemic syndrome 0 0 1 (2) 1 (1)
Fibrosis and tubular atrophy 0 0 4 (10) 4 (3)
Total 0 4 (6) 10 (24) 14 (11)
Graft survival, excluding deaths. N at risk (survival [%])
Month 12 18 (100) 56 (93.7) 32 (76.2) 106 (89)
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Month 36 12  (100)
nd 2 arteries (1–3). No arteries were visualised in 11 biopsies
9%). In total, 19 biopsies (15%) obtained a score of 0–3 points,
3 biopsies (51%) obtained a score of 4–5 points and 42 biopsies
34%) obtained a score of 6–8 points.
Table 4 Table 4 shows both the overall results and the
esults obtained in each of the histological categories. Follow-
ng transplantation, 68% of grafts functioned immediately, 8%
ever functioned and all others functioned after a mean of
0 days. A total of 8% of patients received boluses of corti-
osteroids due to a suspicion of acute rejection. Four patients
3%) died during the ﬁrst year after the transplant. A total of
4 patients (11%) lost the graft in that period of time, in 8
ases due to arterial or venous graft thrombosis (4 from the
–8 histological group and the other 4 from the 4–5 histolog-
cal group). Four patients from the 6–8 histology group lost
he graft with evidence of ﬁbrosis, tubular atrophy and non-
peciﬁc chronic vascular lesions. Overall survival for the grafts,
xcluding deaths, was 89% after the ﬁrst and second year and
4% after the third year.
The relationship between the score obtained in the pre-
mplantation kidney biopsy and eGFR one year after transplant
as analysed in 110 patients. A total of 14 patients were
iscarded from the analysis: Four due to death in the ﬁrst
ear post-transplant, 8 because graft thrombosis, one due to
aemolytic-uraemic syndrome and one owing to graft loss
ssociated with post-operative bleeding. A total of 4 patients
rom the 6–8 group who lost the graft with already reported
esions from ﬁbrosis and tubular atrophy were included. These
atients were assigned a ﬁltration rate of 10 ml/min/1.73 m2
ne year after transplant. Eighteen patients (16%) obtained a
umulative score of 0–3 points, 56 patients (51%) obtained val-
es of 4–5 points and 36 patients (33%) obtained an assessment
f 6–8 points. The biopsies showed a median (Q1-Q3) of 48
lomeruli (33–73) and 2.3 arteries (1–3). No arteries were visu-
lised in 9 biopsies (8%). The age of the donors with a score of
–8 was greater than all other groups, without signiﬁcant dif-
erences being recorded in any of the other baseline clinical or33 (93.7) 15 (76.2) 62 (89)
27 (84.8) 6 (76.2) 45 (84)
demographic characteristics analysed. Regarding clinical out-
comes, the incidence of patients with delayed graft function
was 4 (22%) in the 0–3 group, 14 (25%) in the 4–5 group and
11 (31%) in the 6–8 category (p = 0.80). The time of initiation of
graft function was similar in the 3 groups. Nine patients had
acute rejection: one (6%), 6 (11%) and 2 (6%), in the 0–3, 4–5 and
6–8 groups respectively (p = 0.72). Graft survival 3 years after
transplant, excluding deaths, was 100% in the 0–3 group, 91%
in the 4–5 group and 89% in the 6–8 group (Table 5 Table 5).
Regarding eGFR, the primary study outcome, statistical dif-
ferences were detected. Mean (SD) eGFR for the 6–8 group
(38.5 [14.1] ml/min/1.73 m2) was lower than that reached in the
group with a score of 4–5 (46.3 [15.7] ml/min/1.73 m2 [p = 0.03])
and that achieved in the 0–3 group (49.6 [12.5] ml/min/1.73 m2
[p = 0.04]). Similarly, a signiﬁcant correlation (p = 0.04) was
detected between biopsy score and categorical distribution of
eGFR one year after transplant. Patients with a higher score
had a more  unfavourable distribution (Table 6 Table 6).
The incidence of patients with poor renal function one
year after transplant, eGFR < 30 ml/min/1.73 m2, was 7 (19%)
in the 6–8 group, 8 (14%) in the 4–5 group and zero in
patients with a score of 0–3. These differences were not
statistically signiﬁcant (p = 0.17). In the univariate logistic
regression analysis, which analysed the incidence of patients
with an eGFR < 30 ml/min/1.73 m2 one year after transplant,
the variables that showed a correlation with a p-value < 0.20
were dialysis method (haemodialysis vs peritoneal dialysis),
delayed graft function, acute rejection, donor HTA, donor
diabetes mellitus and ﬁnal biopsy histological score. Tubu-
lar atrophy, interstitial ﬁbrosis, hyaline arteriolopathy and
myointimal elastosis assessed individually also had a p < 0.20.
Delayed graft function was the only variable that had a statisti-
cally signiﬁcant association (p < 0.05). In the ﬁnal multivariate
model (Table 7 Table 7), the variables that showed a signiﬁcant
correlation were delayed graft function and acute rejection.
The score for histological damage for the biopsies, the 6–8
group vs the 0–5 group, had a non-signiﬁcant adjusted OR of
38  n e f r o l o g i a. 2 0 1 6;3  6(1):33–41
Table 5 – Clinical characteristics of the 110 transplants included in the post-transplant renal function analysis.
Variable Biopsy score p
0–3 4–5 6–8
No. of transplants (%) 18 (16) 56 (51) 36 (33)
Donors’ age, years, mean (SD) 71.4 (4.3) 71.3 (5.3) 74.3 (3.9) 0.01
Male donors, N (%) 5 (28) 20 (35) 15 (42) 0.45
Donors’ cause of death, N (%)
Cerebral haemorrhage 16 (89) 52 (93) 27 (75) 0.06
Traumatic brain injury 0  2 (3.5) 6 (17)
Other 2 (11) 2 (3.5) 3 (8)
Donors with a prior history of HTA, N (%) 7 (39) 25 (45) 18 (50) 0.72
Donors with a prior history of diabetes, N (%) 0 8 (14) 7 (19) 0.11
Donor’s creatinine, mg/dl, mean (SD) 0.61 (0.10) 0.65 (0.16) 0.71 (0.19) 0.11
Donor’s MDRD-4 glomerular ﬁltration rate, ml/min/1.73 m2, mean (SD) 112 (22) 109 (28) 105 (30) 0.64
Cold ischaemia, hours, mean (SD) 18.7 (2.9) 18.3 (3.8) 18.4 (3.4) 0.95
Recipients’ age, years, mean (SD) 64.8 (6.2) 66.9 (6.4) 67.7 (6.3) 0.28
Male recipients, N (%) 10 (56) 38 (68) 28 (78) 0.25
Retransplants, N (%) 3 (17) 5 (9) 2 (6) 0.44
HLA A-B-DR incompatibilities, N (%)
0–2 4 (22) 13 (23) 3 (8) 0.08
3–4 11 (61) 40 (72) 32 (89)
5–6 3 (17) 3 (5) 1 (3)
Current PRA, N (%)
Negative 15 (83) 50 (89) 31 (86) 0.36
1–50 3 (17) 6 (11) 3 (8)
>50 0 0 2 (6)
Method of dialysis, N (%)
Haemodialysis 10 (56) 40 (71) 28 (78) 0.23
Peritoneal dialysis 8 (44) 16 (29) 8 (22)
Delayed graft function, N (%) 4  (22) 14 (25) 11 (31) 0.80
Time of start of effective function, days, mean (SD) 10.7  (5.6) 10.5 (6.1) 9.1 (6.9) 0.84
Clinical rejection in the ﬁrst year, N (%) 1 (6) 6 (11) 2 (6) 0.72
Graft survival, excluding deaths. N at risk (survival [%])
Month 12 18 (100) 56 (100) 32 (89) 0.14a
Month 24 14 (100) 33 (100) 15 (89)
Month 36 12 (100) 27 (91) 6 (89)
Month 12 proteinuria/creatinine, N (%)
<0.3 14 (78) 34 (62) 22 (73.3) 0.63
0.3–1 4 (22) 16 (29) 7 (23.3)
>1 0 5 (9) 1 (3.3)
a Mantel log-rank test.
Table 6 – Association between score for lesions from preimplantation biopsies and MDRD-4 estimated glomerular
ﬁltration rate (ml/min/1.73 m2) one year after transplant.
Variables Biopsy score p
0–3 4–5 6–8
No. of transplants 18 56 36
Glomerular ﬁltration rate, mean (SD) 49.6 (12.5) 46.3 (15.7) 38.5 (14.1) 0.01a
Glomerular ﬁltration rate categorised into functional stages, N (%)
<30b OR 8 (14) 7 (19)
30–59 14 (78) 38 (68) 28 (78)
≥60 4 (22) 10 (18) 1 (3) 0.04c
a ANOVA test. Post hoc contrast, Bonferroni test: 6–8 group vs 0–3 group p = 0.03. 6–8 group vs 4–5 group p = 0.04.
b Includes 4 patients, from the 6–8 group, with graft loss who restarted dialysis in the ﬁrst year after transplant and were assigned a ﬁltration
rate of 10 ml (min/1.73 m2).
c Fisher’s exact test.
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Table 7 – Multivariate logistic regression that analyses as
an endpoint the presence of an eGFR < 30 ml/min/1.73 m2
one year after transplant.
Variable OR (95% CI) p
Delayed graft function 6.3 (1.9–21.3) 0.03
Acute rejection 5.8 (1.1–31) 0.04
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poor renal function one year after transplant. This is a mat-Biopsy score of 6–8 vs 0–5 2.2 (0.7–7.3) 0.20
.2 (95% CI, 0.7–7.3). In these regression analyses, the biopsy
core was categorised into 2 groups, 0–5 and 6–8, owing to
he fact that none of the patients in the 0–3 group had an
GFR < 30 ml/min/1.73 m2.
iscussion
e  have presented the results of a follow-up study of 124
ransplant recipients of a kidney from older donors in whom
 preimplantation kidney biopsy had been performed. The
verall results achieved in terms of mortality, graft survival,
raft thrombosis, initial graft functioning, acute rejection and
lomerular ﬁltration rate were consistent with those reported
n the literature in transplants performed with a similar clin-
cal proﬁle.3,16
The main aim of our study was to assess the relationship
etween the degree of severity of the histological lesions from
he kidney biopsies performed and eGFR one year after trans-
lant. The studies that have examined the prognostic value of
reimplantation kidney biopsy are heterogeneous in terms of
oth methodology and results obtained. Glomerulosclerosis of
he donor was the most evidenced initial lesion. Impairment
20% was associated with poorer graft clinical course.17,18
ccording to the data from the OPTN/UNOS, with 2096 kid-
eys biopsied, only the kidneys with glomerulosclerosis <6%
ad slightly better graft survival after 5 years than all other
roups.19 Vascular and tubular-interstitial lesions also were
ssociated with worse clinical course outcomes.20–22 With the
im of improving the prognostic utility, several scales have
een proposed to produce an overall score for prior kidney
esions. The most widely used are that of Pirani–Remuzzi23
nd the Maryland Aggregate Pathology Index (MAPI).24 Scales
ased on the Banff criteria have also been used, but at this time
here is no speciﬁc proposal for this group.25–30 All of them,
ith their limitations and their methodological differences,
how a correlation between the severity of the histological
esions and the functional evolution of grafts, in terms of
oth glomerular ﬁltration rate and graft survival. However,
nalysis of the ROC curves from the studies conducted has
hown that their discriminatory capacity with respect to graft
urvival is moderate, with area-under-the-curve values of
.7–0.8.12,13,31–33 The scale by O’Valle et al.14,15 used in this
tudy was an empirical proposal developed by pathologists
rom Spain and speciﬁcally designed to assess chronic his-
ological damage from donors’ kidney biopsies. The biopsies
ere processed in parafﬁn, in a procedure that takes more
ime and resources than freezing but allows a better assess-
ent of the different kidney compartments.34
Mean eGFR and incidence of patients with an
GFR < 30 ml/min/1.73 m2 one year after transplant were3 6(1):33–41 39
the primary outcomes of our study. These variables have
already been used previously in other publications, as they
are prognostic factors with a major impact on the survival
of kidney grafts in the medium to long term.29–33,35–38 In
our results, grafts with a score of 6–8 reached a mean
glomerular ﬁltration rate one year after transplant lower
than that achieved in the other 2 groups. This was also the
group that recorded a greater incidence of grafts with a low
eGFR < 30 ml/min/1.73 m2 one year after transplant, although
this difference was not statistically signiﬁcant. The associa-
tion between the severity of the histological impairment from
the preimplantation biopsy and evolutionary eGFR of the graft
has already been reported in other publications.29–33 In our
analysis, delayed graft function and acute rejection were sig-
niﬁcantly associated with poor renal function one year after
transplant, eGFR < 30 ml/min/1.73 m2. Patients from the 6–8
group had a slightly greater incidence of delayed graft func-
tion, which could have inﬂuenced this group’s worse renal
function. Some studies have shown a correlation between
preimplantation kidney lesions of the donor, incidence of
delayed function and evolution of the glomerular ﬁltration
rate of the graft.21,22,27 The incidence of acute rejections was
low, and very similar, in the 3 groups analysed.
In interpreting the results obtained, some considerations
and limitations should be identiﬁed: 1. The histological crite-
ria used in graft acceptance ruled out the use of kidneys with
more severe histological impairment; this hindered assess-
ment of their impact on the results. 2. In the analysis of
glomerular ﬁltration rate one year after transplant, patients
who died or lost the graft in the ﬁrst year after the trans-
plant were excluded, with the exception of 4 graft losses that
were considered to be related to the quality of the kidneys
implanted, with non-speciﬁc lesions of ﬁbrosis and tubular
atrophy in the post-transplant biopsy. These patients were
assigned an eGFR of 10 ml/min/1.73 m2. Graft thromboses were
considered to be technical complications not directly related
to preimplantation parenchymal lesions. 3. The variability
between the diseases that the biopsies analysed was not con-
trolled. 4. Arteries were not observed in 9 biopsies. Hence,
these biopsies were not scored in terms of myointimal elasto-
sis. This points to a potential error in classiﬁcation that may
have included some of these transplants in a lower histolog-
ical group than the one to which they belonged. This fact
could have reduced the clinical differences found between the
groups with higher and lower histological severity. 5. The num-
ber of patients analysed limited the power of the statistical
analyses performed.
With the results of the present study, it may be concluded
that overall transplant outcomes of older kidney donors, with
the acceptance and allocation criteria used, were adequate.
Kidneys with greater structural damage in the preimplanta-
tion biopsy, a histological score of 6–8, had a worse renal
function one year after transplant. This may lead to worse
medium and long term graft survival, as has already been
reported in previous studies.30–33 Delayed graft function was a
signiﬁcant variable that determine the incidence of grafts withter that calls for intervention to improve the results obtained.
Acute rejection also had an impact on subsequent function of
grafts, but the impact in our series was very low.
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In our opinion, the use of kidneys with chronic struc-
tural damage has negative effects on transplant outcomes,
but these negative effects may be acceptable in many  cases,
especially in older recipients. It is difﬁcult to determine the
threshold for histological damage that precludes transplant.
In our study, we  established a precautionary threshold similar
to that used in other histopathological scales.23,28,29 Allowing
kidneys with more  histological impairment would increase
the number of grafts available, but with some presumably
worse overall results. Pre-implantation biopsy has its limi-
tations. It requires locally available trained pathologists, its
individual functional prognostic value is moderate and it may
rule out viable kidneys. However, despite these weaknesses,
preimplantation kidney biopsy makes it possible to determine
the severity of the donor’s kidney lesions. This is informa-
tion that we  consider to be useful, especially in older donors
and donors with associated vascular morbidity. It comple-
ments the usual clinical–laboratory donor assessment and
macroscopic graft assessment, and aids in decision-making
regarding acceptance and allocation of kidneys to be trans-
planted with more  criteria. Future initiatives should rigorously
validate one of the existing scales or modiﬁcations thereof and
arrive at a consensus on their use as a guarantor of the quality
of our activities.
Conﬂicts  of  interest
The authors declare that they have no conﬂicts of interest.
Acknowledgements
We  would like to thank the transplant coordinators at Hospital
Universitario Cruces for their collaboration in obtaining donor
data.
 e  f  e  r  e  n  c  e  s
1. Ojo AO, Hanson JA, Meier-Kriesche HU, Okechukwu CN, Wolfe
RA, Leichtman AB, et al. Survival in recipients of marginal
cadaveric donor kidneys compared with other recipients and
wait-listed transplant candidates. J Am Soc Nephrol.
2001;12:589–97.
2. Rao PS, Merion RM, Ashby VB, Port FK, Wolfe RA, Kayler LK.
Renal transplantation in elderly patients older than 70 years
of  age: results from the Scientiﬁc Registry of Transplant
Recipients. Transplantation. 2007;83:1069–74.
3. Pascual J, Zamora J, Pirsch JD. A systematic review of kidney
transplantation from expanded criteria donors. Am J Kidney
Dis. 2008;52:553–86.
4. Heldal K, Hartmann A, Grootendorst DC, de Jager DJ, Leivestad
T, Foss A, et al. Beneﬁt of kidney transplantation beyond 70
years of age. Nephrol Dial Transplant. 2010;25:1680–7.
5. Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie
BW,  Young EW, et al. Donor characteristics associated with
reduced graft survival: an approach to expanding the pool of
kidney donors. Transplantation. 2002;74:1281–6.
6. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion
RM.  Expanded criteria donors for kidney transplantation. Am
J  Transplant. 2003;3 Suppl. 4:114–25.6;3  6(1):33–41
7. Nyberg SL, Matas AJ, Kremers WK,  Thostenson JD, Larson TS,
Prieto M, et al. Improved scoring system to assess adult donor
cadaver renal transplantation. Am J Transplant.
2003;3:715–21.
8. Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad
spectrum of quality in deceased donor kidneys. Am J
Transplant. 2005;5:757–65.
9. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA,
Merion RM, et al. A comprehensive risk quantiﬁcation score
for deceased donor kidneys: the kidney donor risk index.
Transplantation. 2009;88:231–6.
0. Watson CJ, Johnson RJ, Birch R, Collett D, Bradley JA. A
simpliﬁed donor risk index for predicting outcome after
deceased donor kidney transplantation. Transplantation.
2012;93:314–8.
1. Jochmans I, Pirenne J. Graft quality assessment in kidney
transplantation: not an exact science yet! Curr Opin Organ
Transplant. 2011;16:174–9.
2. Hopfer H, Kemény E. Assessment of donor biopsies. Curr
Opin Organ Transplant. 2013;18:306–12.
3. Dare AJ, Pettigrew GJ, Saeb-Parsy K. Preoperative assessment
of the deceased-donor kidney: from macroscopic appearance
to  molecular biomarkers. Trasplantation. 2014;97:797–807.
4. O’Valle F, Gómez-Morales M, Osuna A, Aguilar M,  Olmo A,
Asensio C, et al. Valoración protocolizada de la biopsia renal
de  donante an˜oso. Propuesta de un nuevo sistema de
puntuación. Nefrología. 2000;20 Suppl. 4:83.
5. O’Valle F, Gómez-Morales M, Reguero ME, Aguilar M,  Olmo A,
Espigares B, et al. Morfología y marcadores moleculares de
lesión de rin˜ones de donantes an˜osos. SEDYT. 2000;21:
1–7.
6. Stratta RJ, Rohr MS, Sundberg AK, Farney AC, Hartmann EL,
Moore PS, et al. Intermediate-term outcomes with expanded
criteria deceased donors in kidney transplantation. A
spectrum or specter of quality? Ann Surg. 2006;243:594–603.
7. Gaber LW, Moore LW, Alloway RR, Amiri MH,  Vera SR, Gaber
AO, et al. Glomerulosclerosis as a determinant of
postransplant function of older donor renal allografts.
Transplantation. 1995;60:334–9.
8. Escofet X, Osman H, Grifﬁths DFR, Woydag S, Jurewicz WA.
The presence of glomerular sclerosis at time zero has a
signiﬁcant impact on function after cadaveric renal
transplantation. Transplantation. 2003;75:344–6.
9. Bajwa M, Cho YW, Pham PT, Shah T, Danovitch G, Wilkinson
A,  et al. Donor biopsy and kidney transplant outcomes: an
analysis using the Organ Procurement and Transplantation
Network/United Network for Organ Sharing. Transplantation
(OPTN-UNOS) Database. 2007;84:1399–405.
0. Arias LF, Blanco J, Sánchez-Fructuoso A, Prats D, Duque E,
Sáiz-Pardo M, et al. Histologic assessment of donor kidneys
and  graft outcome: multivariate analyses. Transplant Proc.
2007;39:1368–70.
1. Matignon M, Desvaux D, Noël LH, Roudot-Thoraval F, Thervet
E,  Audard V, et al. Arteriolar hyalinization predicts delayed
graft function in deceased donor renal transplantation.
Transplantation. 2008;86:1002–5.
2. Cockﬁeld SM, Moore RB, Todd G, Solez K, Gourishankar S. The
prognostic utility of deceased donor implantation biopsy in
determining function and graft survival after kidney
transplantation. Transplantation. 2010;89:559–66.
3. Remuzzi G, Grin˜o J, Ruggenenti P, Beatini M,  Cole EH, Mildford
EL, et al. Early experience with dual kidney transplantation in
adults using expanded donor criteria. J Am Soc Nephrol.
1999;10:2591–8.
4. Munivenkatappa RB, Schweitzer EJ, Papadimitriou JC,
Drachemberg CB, Thom KA, Perencevich EN, et al. The
Maryland Aggregate Pathology Index: a deceased donor
kidney biopsy scoring system for predicting graft failure. Am J
Transplant. 2008;8:2316–24.
 0 1 6;
2
2
2
2
2
3
3
3
3
3
3
3
3n e f r o l o g i a. 2
5. Racusen L, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo
T, et al. The Banff 97 working classiﬁcation of kidney allograft
pathology. Kidney Int. 1999;55:713–23.
6. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al.
Banff 07 classiﬁcation of renal allograft pathology: updates
and future directions. Am J Transplant. 2008;8:
753–60.
7. Lopes JA, Moreso F, Riera L, Carrera M, Ibernon M, Fulladosa X,
et  al. Evaluation of pre-implantation kidney biopsies:
comparison of Banff criteria to a morphometric approach.
Kidney Int. 2005;67:1595–600.
8. Navarro MD, López-Andreu M, Rodríguez-Benot A,
Ortega-Salas R, Agüera ML, López-Rubio F, et al. Signiﬁcance
of  preimplantation analysis of kidney biopsies from
expanded criteria donors in long-term outcome.
Transplantation. 2011;91:432–9.
9. Azancot MA, Moreso F, Salcedo M, Cantarell C, Perello M,
Torres IB, et al. The reproducibility and predictive value on
outcome of renal biopsies from expanded criteria donors.
Kideny Int. 2014;85:1161–8.
0. Kahu J, Kyllönen L, Räsänen-Sokolowski A, Salmela K. Donor
risk score and baseline biopsy CADI value predict kidney graft
outcome. Clin Transplant. 2011;25:E276–83.1. Anglicheau D, Loupy A, Lefaucheur C, Pessione F, Létourmeau
I,  Côté I, et al. A simmple clínico-histopathological composite
scoring system is highly predictive of graft outcomes in
marginal donors. Am J Transplant. 2008;8:2325–34.
33 6(1):33–41 41
2. Hofer J, Regele H, Böhmig GA, Gutjahr G, Kikic Z, Mühlbacher
F, et al. Pre-implant biopsy predicts outcome of single-kidney
transplantation independent of clinical donor variables.
Transplantation. 2014;97:426–32.
3. Philosophe B, Malat GE, Soundararajan S, Barth RN,
Manitpisikul W,  Wilson NS, et al. Validation of the Maryland
Aggregate Pathology Index (MAPI), a preimplantation scoring
system that predicts graft outcome. Clin Transplant.
2014;28:897–905.
4. Serón D, Anaya F, Marcén R, García del Moral  R,
Vázquez-Martul E, Alarcón A, et al. Recomendaciones para la
indicación, obtención, procesamiento y evaluación de
biopsias en el trasplante renal. Nefrología. 2008;28:385–96.
5. Hariharan S, McBride MA, Cherikh WS,  Tolleris CB, Bresnahan
BA,  Johnson CP. Post-transplant renal function in the ﬁrst
year predicts long-term kidney transplant survival. Kidney
Int. 2002;62:311–8.
6. Marcén R, Pascual J, Tenorio M, Ocan˜a EJ, Teruel JL, Villafruela
JJ,  et al. Chronic kidney disease in renal transplant recipients.
Transplant Proc. 2005;37:3718–20.
7. Salvadori M, Rosati A, Bock A, Chapman J, Dussol B, Fritsche
L,  et al. Estimated one-year glomerular ﬁltration rate is the
best predictor of long-term graft function following renal
transplant. Transplantation. 2006;81:202–6.
8. Kasiske BL, Israni AK, Snyder JJ, Skeans MA. The relationship
between kidney function and long-term graft survival after
kidney transplant. Am J Kidney Dis. 2011;57:466–75.
